SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC
International Immunopharmacology · 2024-07 · 136 · 112367
DOI: 10.1016/j.intimp.2024.112367 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-07. Verfasst von Shiqi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR Chi…. Hauptthemen laut MEDLINE: Ferroptosis, Liver Neoplasms, Carcinoma, Hepatocellular, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
SLC25A19 is a mitochondrial thiamine pyrophosphate (TPP) carrier that mediates TPP entry into the mitochondria. SLC25A19 has been recognized to play a crucial role in many metabolic diseases, but its role in cancer has not been clearly reported. Based on clinical data from The Cancer Genome Atlas (TCGA), the following parameters were analyzed among HCC patients: SLC25A19 expression, enrichment analyses, immune infiltration, ferroptosis and prognosis analyses. In vitro, the SLC25A19 high expression was validated by qRT-PCR and Immunohistochemistry. Subsequently, a series of cell function experiments, including CCK8, EdU, clone formation, trans-well and scratch assays, were conducted to illustrate the effect of SLC25A19 on the growth and metastasis of cancer cells. Meanwhile, indicators related to ferroptosis were also detected. SCL25A19 is highly expressed in HCC and predicts a poor prognosis. Elevated SLC25A19 expression in HCC patients was markedly associated with T stage, pathological status (PS), tumor status (TS), histologic grade (HG), and AFP. Our results indicate that SLC25A19 has a generally good prognosis predictive and diagnostic ability. The results of gene enrichment analyses showed that SLC25A19 is significantly correlated with immune infiltration, fatty acid metabolism, and ferroptosis marker genes. In vitro experiments have confirmed that silencing SLC25A19 can significantly inhibit the proliferation and migration ability of cancer cells and induce ferroptosis in HCC. In conclusion, these findings indicate that SLC25A19 is novel prognostic biomarker related to immune invasion and ferroptosis in HCC, and it is an excellent candidate for therapeutic target against HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First…
Zitieren
APA
Liu, S., Zhang, P., Wu, Y., Zhou, H., Wu, H., Jin, Y., Wu, D., & Wu, G. (2024). SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC. International Immunopharmacology, 136, 112367. https://doi.org/10.1016/j.intimp.2024.112367
Vancouver
Liu S, Zhang P, Wu Y, Zhou H, Wu H, Jin Y, et al. SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC. International Immunopharmacology. 2024;136:112367. doi:10.1016/j.intimp.2024.112367
BibTeX
@article{Liu2024,
author = {Liu, Shiqi and Zhang, Pengjie and Wu, Yubo and Zhou, Haonan and Wu, Haomin and Jin, Yifan and Wu, Di and Wu, Gang},
title = {SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC},
journal = {International Immunopharmacology},
year = {2024},
volume = {136},
pages = {112367},
doi = {10.1016/j.intimp.2024.112367}
}
EUVIMED